权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Kaiser Washington Vaccine and Treatment Evaluation Unit

凯撒华盛顿疫苗和治疗评估单位

基本信息

批准号：
10493519
负责人：
LISA A JACKSON
金额：
$ 31.49万
依托单位：
KAISER FOUNDATION RESEARCH INSTITUTE
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-05-11 至 2023-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10493519
关键词：
Acute respiratory infection Address Adjuvant Adult Age Anti-Infective Agents Area Avian Influenza Biological Products Biomedical Research Cancer Research Network Caring Centers for Disease Control and Prevention (U.S.)Child China Clinical Research Clinical Trials Collaborations Communicable Diseases Communities Computerized Medical Record Conduct Clinical Trials Contracts Data Development Devices Diagnostic Diagnostic Equipment Doctor of Philosophy Drug Kinetics Elderly Elements Emerging Communicable Diseases Enrollment Evaluation Fostering Group Structure HIV Vaccine Trials Network Health Health Policy Human Immunologics Immunology Infection Infectious Diseases Research Influenza Influenza A Virus, H1N1 Subtype Influenza A Virus, H7N9 Subtype Influenza prevention Infrastructure International Kentucky Laboratories Leadership Malaria Malaria Vaccines Medical center Modeling National Institute of Allergy and Infectious Disease Outpatients Persons Pharmacy Schools Pharmacy facility Phase Pneumococcal Infections Population Population Heterogeneity Pregnant Women Preventive Protocols documentation Public Health Research Research Institute Research Personnel Research Priority Resources Respiratory Tract Infections Rhea Schedule Science Seasons Site Structure Therapeutic Tuberculosis U-Series Cooperative Agreements United States National Institutes of Health Universities Vaccine Clinical Trial Vaccines Washington Work care systems clinical research site design experience experimental study health plan high risk population influenza infection influenza outbreak influenza virus vaccine innovation malaria infection member multidisciplinary neglected tropical diseases novel vaccines operation pandemic disease pandemic influenza pharmacokinetic model prevent programs public health research research study response supportive environment therapeutic candidate training opportunity vaccine candidate vaccine development vaccine effectiveness vaccine trial working group

项目摘要

Abstract Infectious diseases continue to pose a significant threat to human health, with many types of infections having far-reaching, global consequences. The ability to develop vaccines, therapeutics, devices and diagnostics to prevent, treat, and identify infectious diseases is a critical public health need. Clinical trials are an integral component of these development efforts. Since the 1960s the Vaccine and Treatment Evaluation Units (VTEUs) have conducted trials that have evaluated promising vaccine and therapeutic candidates for infectious diseases such as influenza (including pandemic and avian influenza), malaria, tuberculosis, pneumococcal infection, in children and adults. In addition, the VTEUs have quickly launched trials in response to newly emerging and reemerging infectious diseases, such as the 2009 influenza H1N1 pandemic, and Waves 1 and 5 of the H7N9 avian influenza outbreaks in China. These efforts have provided data that informed public health policy. This proposal is in response to a new VTEU structure which will involve greater collaboration between the VTEUs, NIAID, and the newly formed Leadership Group structure that are all part of the NIAID Infectious Diseases Clinical Research Consortium (IDCRC). The IDCRC will enhance integration and efficiency of operations and, importantly, will foster the collaborative team science approaches now recognized as optimal to address important and complicated public health research priorities. Under the new cooperative agreement, the Kaiser Washington VTEU will continue to conduct clinical research and trials, including trials conducted under an IND or IDE, within the Kaiser Washington integrated care system to contribute to the priority research foci of NIAID. These priority areas include malaria, influenza and other respiratory infections, acute respiratory infections and include clinical trials, including human challenge models, and pharmacokinetic studies. The research will be conducted in collaboration with Seattle area infectious disease research partners who will provide scientific expertise, specialized facilities, and advanced immunologic laboratory capabilities. The Kaiser Washington VTEU will also develop and maintain surge capacity for clinical site, pharmacy and laboratory operations to enable the rapid initiation of clinical trials and other studies in response to emerging and reemerging infectious disease threats of public health importance.

摘要